http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0686628-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2de3beee83d9c19278da409b72c777a8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00 |
| filingDate | 1995-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0afa53c6e781b1496e57c44be27c487f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23126a522d89a8c24e2563f789d9e86b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a122e19d4ee916ba58db67cc8fd0645 |
| publicationDate | 1995-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0686628-A2 |
| titleOfInvention | Prostaglandin F esters |
| abstract | Prostaglandin F esters of formula (I):n n wherein R 1' is a C₁₋₆ alkyl, a C₄₋₇ carbocycle, or a C₁₋₄ alkyl substituted by a C₄₋₇ carbocycle, the C₄₋₇ carbocycle being optionally substituted by one or more groups independently selected from C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, nitro and trifluoromethyl; n R 2' is a bond or C₁₋₄ alkylene; n R 3' is C₁₋₇ alkyl; and n the 9-hydroxy group is α or β; n with the provisos that:n (i) when the 9-hydroxy group is α then:n (a) R 2' -R 3' is not n-pentyl; and (b) when R 1' is methyl and the 13 and 14 positions are singly bonded or when R 1' is ethyl and the 13 and 14 positions are doubly bonded, then R 2' -R 3' is not 1,1-dimethylpentyl; and (ii) when the 9-hydroxy group is β,n (a) when R 1' is ethyl and the 13 and 14 positions are doubly bonded then R 2' -R 3' is not n-pentyl or 1,1-dimethylpentyl; and (b) when R 2' -R 3' is n-pentyl and the 13 and 14 positions are singly bonded then R 1' is not C₁₋₆ alkyl; nor a cyclodextrin clathrate thereof, possess ocular hypotensive activity at low concentration and low stimulus and are therefore useful for preventing and /or treating glaucoma. n Processes for their preparation and the use of 16,16-dimethyl PGF2β ethyl ester in the treatment of glaucoma are also disclosed. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6197812-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5866602-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5994397-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6369102-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5814660-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9723223-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6025392-A |
| priorityDate | 1994-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 175.